Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin
cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered
weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles
of therapy will be given to determine the anti-tumor response of the new chemotherapy.
Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows
continuing benefit.